Disruption of a transcription network controlled by MEF2 in heart tissue of people with myotonic dystrophy type 1 affects activity of the minute bits of genetic material called microRNAs responsible for fine-tuning expression of proteins.
This was said by researchers from Baylor College of Medicine in a report that appears online in the journal Cell Reports
Myotonic dystrophy type 1 is an inherited form of muscular dystrophy with symptoms starting in early adulthood. Malfunction of the heart involving its ability to beat properly is the second most common cause of death in the disorder, said Dr. Thomas Cooper, professor of pathology & immunology at Baylor and corresponding author of the report.
"Our studies in both mice and human heart tissues identified many microRNAs that are affected," said Cooper.
Myotonic dystrophy occurs because parts of the gene DMPK (dystrophia myotonica-protein kinase) are duplicated abnormally, resulting in what is known as a triplet repeat. While most myotonic dystrophy research has focused on problems related to types of messenger RNAs produced from genes by altered splicing, this study demonstrates additional problems with expression of microRNAs, said Dr. Auinash Kalsotra, assistant professor of biochemistry and the first author on the study, who has now started his own research group at the University of Illinois, Urbana-Champaign.
Cooper, Kalsotra and their colleagues screened approximately 500 microRNAs and found 54 affected. A screen of human myotonic dystrophy cells identified 20 that were down regulated in the heart tissue of patients with myotonic dystrophy. MicroRNAs maintain proper gene activity so abnormal microRNA levels is likely to produce disease.
By investigating why the microRNAs were abnormal, the investigators found that the protein controlling their expression, the transcription factor MEF2, was abnormally low in myotonic dystrophy heart tissue.
MicroRNAs are fairly recently recognized genetic actors that fine tune the levels of messenger RNA, which takes the genetic code to that part of the cell where proteins are made. In this case, MEF2 affects not only the level of activity of genes but also these bits of RNA that fine-tune the proteins associated with the genes.
"This shifted the focus of research. Now a transcription factor is involved," Cooper said. Transcription factors control the expression of genes (the levels of activity). Since MEF2 controls many other genes in addition to those of microRNAs, the results identify additional abnormalities that can help explain some features of the disease.
For example, said Cooper, aberrant microRNAs result in turning on cellular factors that should not be turned on. The protein CELF1, which is upregulated in the disease, is affected by these microRNAs.
"The regulation of genes is very dynamic and finely tuned to respond to changing conditions," he said. "The abnormality that causes this disease disrupts a large network and thus has multiple effects"
Others who took part in this work include,Ravi K. Singh and Chad J. Creighton, of Baylor, and Priyatansh Gurha and Amanda J. Ward, formerly with Baylor and now with The University of Texas Health Science Center at Houston and the Isis Pharmaceuticals in Carlsbad, Calif., respectively.